PCN48 SUNITINIB MALATE PROVIDES ADDITIONAL SURVIVAL AND VALUE FOR MONEY AS A SECOND LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC)—AN ECONOMIC EVALUATION USING BAYESIAN APPROACH
Nov 1, 2007, 00:00
10.1016/S1098-3015(10)65206-0
https://www.valueinhealthjournal.com/article/S1098-3015(10)65206-0/fulltext
Title :
PCN48 SUNITINIB MALATE PROVIDES ADDITIONAL SURVIVAL AND VALUE FOR MONEY AS A SECOND LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC)—AN ECONOMIC EVALUATION USING BAYESIAN APPROACH
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)65206-0&doi=10.1016/S1098-3015(10)65206-0
First page :
Section Title :
Open access? :
No
Section Order :
365